½ÃÀ庸°í¼­
»óǰÄÚµå
1541821

ºÐÁöº´º¯ ½ÃÀå º¸°í¼­ : À¯Çüº°, ¿ëµµº°, Áö¿ªº°(2024-2032³â)

Bifurcation Lesions Market Report by Types (One-Stent, Two-Stent), Application (Coronary Vascular, Peripheral Vascular), and Region 2024-2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: IMARC | ÆäÀÌÁö Á¤º¸: ¿µ¹® 135 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ ºÐÁöº´º¯ ½ÃÀå ±Ô¸ð´Â 2023³â 24¾ï ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. IMARC GroupÀº ÇâÈÄ 2024³âºÎÅÍ 2032³â±îÁö ¼ºÀå·ü(CAGR)Àº 4.6%¸¦ ³ªÅ¸³¾ Àü¸ÁÀ̸ç, 2032³â¿¡´Â 37¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøÇß½À´Ï´Ù.

ºÐÁöº´º¯Àº Áß¿äÇÑ Ãø °¡Áö(SB)ÀÇ ½ÃÀÛ ºÎºÐ¿¡ ÀÎÁ¢ÇÑ °ü»ó µ¿¸ÆÀÇ ÇùÂøÀ» ÀǹÌÇÕ´Ï´Ù. È寮·¯Áø Ç÷·ù¿Í ³ôÀº Àü´Ü ÀÀ·ÂÀ¸·Î ÀÎÇØ µ¿¸Æ °æÈ­¼º ÇöóÅ©°¡ ¹ß»ýÇϱ⠽±½À´Ï´Ù. ºÐ¼®, ÀýÂ÷ ½Ã°£, X¼± Á¶»ç, Àå±â °æ°ú °üÂû µîÀÇ ±â¼úÀ» »ç¿ëÇÏ¿© Ä¡·áµË´Ï´Ù. ¶ÇÇÑ, 3Â÷¿ø(3D) Ç÷°ü Á¶¿µ°ú ¸ÖƼ ½½¶óÀ̽º CT°¡ ºÐ±â°¢ ÃøÁ¤¿¡ ÀÌ¿ëµË´Ï´Ù. Àåºñ, ¿µ»ó Áø´Ü, º¸Á¶ ¾à¹° ¿ä¹ý, ¹ö½ºÅ§·¯ Á¢±ÙÀÇ Áøº¸·Î º¹ÀâÇÑ ºÐÁöº´º¯ÀÇ °ü¸®°¡ ¼¼°èÀûÀ¸·Î °¡´ÉÇØÁö°í ÀÖ½À´Ï´Ù.

ºÐÁöº´º¯ ½ÃÀå µ¿Çâ

°ü»ó µ¿¸Æ Áúȯ(CAD) Áõ°¡´Â ºÐÁöº´º¯ÀÇ ¹ßº´ À§ÇèÀ» ³ôÀÔ´Ï´Ù. À̰ÍÀº ½ÃÀå ¼ºÀåÀ» µÞ¹ÞħÇÏ´Â Áß¿äÇÑ ¿ä¼Ò Áß ÇϳªÀÔ´Ï´Ù. ÀÌ ¿Ü¿¡µµ Çõ½ÅÀûÀÎ ±â±â ½ÂÀÎ, º¸Çè Àû¿ë ¹üÀ§ È®´ë, ¿µ»ó Áø´Ü ¾ç½Ä Çâ»ó µî ½ÃÀåÀÇ ¼ºÀåÀ» °­È­Çϰí ÀÖ½À´Ï´Ù. °Ô´Ù°¡ ÀÇ·á»óÀÇ Áúº´À» ¹ßº´Çϱ⠽¬¿î ³ëÀÎ Àα¸°¡ Áõ°¡Çϰí ÀÖÀ¸¸ç, »óȯÀ» À§ÇØ °¢±¹ Á¤ºÎ°¡ ½Ç½ÃÇϰí ÀÖ´Â Áö¿øÃ¥ÀÌ ½ÃÀå ¼ºÀåÀ» Áö¿øÇϰí ÀÖ½À´Ï´Ù. ÀÇ·á Åõ¾î¸®Áò Áõ°¡, Àúħ½À(MI) ÀýÂ÷¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, ÀÇ·á ÀÎÇÁ¶ó °³¼± µîµµ ½ÃÀå ¼ºÀå¿¡ ±â¿©ÇÏ´Â ¿äÀÎ Áß ÇϳªÀÔ´Ï´Ù. À̿ʹ º°µµ·Î »õ·Î¿î Ä¡·á ±â¼ú¿¡ ´ëÇÑ ¿¬±¸°¡ ÁøÇàµÇ°í ÀÖ´Â °Íµµ ½ÃÀåÀ» °ßÀÎÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, SB Æó»öÀÇ À§ÇèÀÌ ³ô°Å³ª Ä¡¸íÀûÀÎ °á°ú¸¦ ÃÊ·¡ÇÏ´Â º¹ÀâÇÑ ºÐÁöº´º¯¿¡ ´ëÇÑ Szabo 2 ½ºÅÙÆ® ¹æ¹ýÀÇ È¿´ÉÀ» ¿¬±¸Çϰí ÀÖ½À´Ï´Ù. °Ô´Ù°¡ ½ºÅÙÆ®¿Í dz¼±¿¡ ´ëÇÑ ±¤¹üÀ§ÇÑ ÀÓ»ó½ÃÇè°ú ¼÷·ÃµÈ ÀÇ·á Àü¹®°¡ Áõ°¡°¡ ´õÇØÁ® ºÐÁöº´º¯ÀÇ Ä¡·á¿¡ µû¸¥ À§ÇèÀÌ °¨¼ÒÇÏ°í ½ÃÀå¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÀÌ º¸°í¼­¿¡¼­ ´Ù·ç´Â ÁÖ¿ä Áú¹®

  • 2023³â ¼¼°èÀÇ ºÐÁöº´º¯ ½ÃÀå ±Ô¸ð´Â?
  • 2024³âºÎÅÍ 2032³â±îÁö ¼¼°è ºÐÁöº´º¯ ½ÃÀåÀÇ ¿¹»ó ¼ºÀå·üÀº?
  • ¼¼°èÀÇ ºÐÁöº´º¯ ½ÃÀå¿¡ ´ëÇÑ COVID-19ÀÇ ¿µÇâÀº?
  • ¼¼°èÀÇ ºÐÁöº´º¯ ½ÃÀåÀ» °ßÀÎÇÏ´Â ÁÖ¿ä ¿äÀÎÀº?
  • ¼¼°èÀÇ ºÐÁöº´º¯ ½ÃÀåÀÇ ¿ëµµº° ³»¿ªÀº?
  • ¼¼°è ºÐÁöº´º¯ ½ÃÀåÀÇ ÁÖ¿ä Áö¿ªÀº?
  • ¼¼°è ºÐÁöº´º¯ ½ÃÀå ½ÃÀåÀÇ ÁÖ¿ä ÁøÃâ±â¾÷Àº?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹üÀ§ ¹× Á¶»ç ¹æ¹ý

  • Á¶»çÀÇ ¸ñÀû
  • ÀÌÇØ°ü°èÀÚ
  • µ¥ÀÌÅÍ ¼Ò½º
    • 1Â÷ Á¤º¸
    • 2Â÷ Á¤º¸
  • ½ÃÀå ÃßÁ¤
    • »óÇâ½Ä Á¢±Ù
    • ÇÏÇâ½Ä Á¢±Ù
  • Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ¼­¹®

  • °³¿ä
  • ÁÖ¿ä ¾÷°è µ¿Çâ

Á¦5Àå ¼¼°èÀÇ ºÐÁöº´º¯ ½ÃÀå

  • ½ÃÀå °³¿ä
  • ½ÃÀå ½ÇÀû
  • COVID-19ÀÇ ¿µÇâ
  • ½ÃÀå ¿¹Ãø

Á¦6Àå ½ÃÀå ³»¿ª : À¯Çüº°

  • 1 ½ºÅÙÆ®
  • 2 ½ºÅÙÆ®

Á¦7Àå ½ÃÀå ³»¿ª : ¿ëµµº°

  • °ü»óµ¿¸Æ Ç÷°ü
  • ¸»ÃÊ Ç÷°ü

Á¦8Àå ½ÃÀå ³»¿ª : Áö¿ªº°

  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • ÀϺ»
    • Àεµ
    • Çѱ¹
    • È£ÁÖ
    • Àεµ³×½Ã¾Æ
    • ±âŸ
  • À¯·´
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ¿µ±¹
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ·¯½Ã¾Æ
    • ±âŸ
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ±âŸ
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ³»¿ª : ±¹°¡º°
    • ½ÃÀå ¿¹Ãø

Á¦9Àå SWOT ºÐ¼®

  • °³¿ä
  • °­Á¡
  • ¾àÁ¡
  • ±âȸ
  • À§Çù

Á¦10Àå ¹ë·ùüÀÎ ºÐ¼®

Á¦11Àå Porter's Five Forces ºÐ¼®

  • °³¿ä
  • ±¸¸ÅÀÚÀÇ Çù»ó·Â
  • °ø±Þ±â¾÷ÀÇ Çù»ó·Â
  • °æÀïµµ
  • ½Å±Ô Âü°¡¾÷üÀÇ À§Çù
  • ´ëüǰÀÇ À§Çù

Á¦12Àå °¡°Ý ºÐ¼®

Á¦13Àå °æÀï ±¸µµ

  • ½ÃÀå ±¸Á¶
  • ÁÖ¿ä ±â¾÷
  • ÁÖ¿ä ±â¾÷ ÇÁ·ÎÆÄÀÏ
    • Boston Scientific Corporation
    • Cardinal Health
    • Medtronic plc
    • Spectranetics(Koninklijke Philips NV)
    • Terumo Corporation
AJY 24.09.24

The global bifurcation lesions market size reached US$ 2.4 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 3.7 Billion by 2032, exhibiting a growth rate (CAGR) of 4.6% during 2024-2032.

A bifurcation lesion refers to the narrowing of the coronary artery adjacent to the origin of a significant side branch (SB). It is prone to develop atherosclerotic plaque due to turbulent blood flow and high shear stress. It is treated using techniques like analysis, procedure duration, X-ray exposure, and long-term follow-up. Moreover, three-dimensional (3D) angiography and multi-slice computed tomography are utilized for measuring the bifurcation angles. With the advances in devices, imaging, adjunctive pharmacotherapy, and vascular access, the management of complex cases of bifurcation lesions is becoming possible worldwide.

Bifurcation Lesions Market Trends:

A significant rise in the occurrence of coronary artery disease (CAD) is increasing the risk of developing bifurcation lesions. This represents one of the key factors bolstering the market growth. Besides this, the approval of innovative devices, increasing insurance coverage, and improving imaging modalities are also strengthening the market growth. Moreover, the rising geriatric population, which is more likely to develop medical ailments, along with supportive initiatives undertaken by governments of various countries for reimbursement, is supporting the market growth. The increasing medical tourism, the escalating demand for minimally invasive (MI) procedures and the improving healthcare infrastructure are some of the other factors contributing to the growth of the market. Apart from this, the ongoing research on novel treatment techniques is driving the market. For instance, researchers are studying the effectiveness of the Szabo 2-stent technique for complex bifurcations lesions with high compromise risk or fatal consequences of SB occlusion. Furthermore, a wide range of clinical trials on stents and balloons, in confluence with the increasing number of skilled healthcare professionals, is anticipated to decrease risks associated with bifurcation lesions treatment and influence the market positively.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global bifurcation lesions market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on types and application.

Breakup by Types:

One-Stent

Two-Stent

Breakup by Application:

Coronary Vascular

Peripheral Vascular

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Boston Scientific Corporation, Cardinal Health, Medtronic plc, Spectranetics (Koninklijke Philips N.V.) and Terumo Corporation.

Key Questions Answered in This Report

  • 1. What was the size of the global bifurcation lesions market in 2023?
  • 2. What is the expected growth rate of the global bifurcation lesions market during 2024-2032?
  • 3. What has been the impact of COVID-19 on the global bifurcation lesions market?
  • 4. What are the key factors driving the global bifurcation lesions market?
  • 5. What is the breakup of the global bifurcation lesions market based on the application?
  • 6. What are the key regions in the global bifurcation lesions market?
  • 7. Who are the key players/companies in the global bifurcation lesions market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Bifurcation Lesions Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Types

  • 6.1 One-Stent
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Two-Stent
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Application

  • 7.1 Coronary Vascular
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Peripheral Vascular
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Region

  • 8.1 North America
    • 8.1.1 United States
      • 8.1.1.1 Market Trends
      • 8.1.1.2 Market Forecast
    • 8.1.2 Canada
      • 8.1.2.1 Market Trends
      • 8.1.2.2 Market Forecast
  • 8.2 Asia-Pacific
    • 8.2.1 China
      • 8.2.1.1 Market Trends
      • 8.2.1.2 Market Forecast
    • 8.2.2 Japan
      • 8.2.2.1 Market Trends
      • 8.2.2.2 Market Forecast
    • 8.2.3 India
      • 8.2.3.1 Market Trends
      • 8.2.3.2 Market Forecast
    • 8.2.4 South Korea
      • 8.2.4.1 Market Trends
      • 8.2.4.2 Market Forecast
    • 8.2.5 Australia
      • 8.2.5.1 Market Trends
      • 8.2.5.2 Market Forecast
    • 8.2.6 Indonesia
      • 8.2.6.1 Market Trends
      • 8.2.6.2 Market Forecast
    • 8.2.7 Others
      • 8.2.7.1 Market Trends
      • 8.2.7.2 Market Forecast
  • 8.3 Europe
    • 8.3.1 Germany
      • 8.3.1.1 Market Trends
      • 8.3.1.2 Market Forecast
    • 8.3.2 France
      • 8.3.2.1 Market Trends
      • 8.3.2.2 Market Forecast
    • 8.3.3 United Kingdom
      • 8.3.3.1 Market Trends
      • 8.3.3.2 Market Forecast
    • 8.3.4 Italy
      • 8.3.4.1 Market Trends
      • 8.3.4.2 Market Forecast
    • 8.3.5 Spain
      • 8.3.5.1 Market Trends
      • 8.3.5.2 Market Forecast
    • 8.3.6 Russia
      • 8.3.6.1 Market Trends
      • 8.3.6.2 Market Forecast
    • 8.3.7 Others
      • 8.3.7.1 Market Trends
      • 8.3.7.2 Market Forecast
  • 8.4 Latin America
    • 8.4.1 Brazil
      • 8.4.1.1 Market Trends
      • 8.4.1.2 Market Forecast
    • 8.4.2 Mexico
      • 8.4.2.1 Market Trends
      • 8.4.2.2 Market Forecast
    • 8.4.3 Others
      • 8.4.3.1 Market Trends
      • 8.4.3.2 Market Forecast
  • 8.5 Middle East and Africa
    • 8.5.1 Market Trends
    • 8.5.2 Market Breakup by Country
    • 8.5.3 Market Forecast

9 SWOT Analysis

  • 9.1 Overview
  • 9.2 Strengths
  • 9.3 Weaknesses
  • 9.4 Opportunities
  • 9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

  • 11.1 Overview
  • 11.2 Bargaining Power of Buyers
  • 11.3 Bargaining Power of Suppliers
  • 11.4 Degree of Competition
  • 11.5 Threat of New Entrants
  • 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

  • 13.1 Market Structure
  • 13.2 Key Players
  • 13.3 Profiles of Key Players
    • 13.3.1 Boston Scientific Corporation
      • 13.3.1.1 Company Overview
      • 13.3.1.2 Product Portfolio
      • 13.3.1.3 Financials
      • 13.3.1.4 SWOT Analysis
    • 13.3.2 Cardinal Health
      • 13.3.2.1 Company Overview
      • 13.3.2.2 Product Portfolio
      • 13.3.2.3 Financials
      • 13.3.2.4 SWOT Analysis
    • 13.3.3 Medtronic plc
      • 13.3.3.1 Company Overview
      • 13.3.3.2 Product Portfolio
    • 13.3.4 Spectranetics (Koninklijke Philips N.V.)
      • 13.3.4.1 Company Overview
      • 13.3.4.2 Product Portfolio
    • 13.3.5 Terumo Corporation
      • 13.3.5.1 Company Overview
      • 13.3.5.2 Product Portfolio
      • 13.3.5.3 Financials
      • 13.3.5.4 SWOT Analysis
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦